User login
Enter your username and password here in order to log in on the website:
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- Compassionate use - VX809
- Hello, I turn to you with a question concerning VX-809. Vertex reported at the presentation of data (Phase 3 Ivacaftor / Lumacaftor from June 24th, 2014) about a "compassionate use" program [comment of the translator: a compassionate use program describes the tolerated usage of a drug that is ...
- 13.10.2014
- Compassionate use program for deltaF508 patient
- Hello In the press release dated on June 24th, 2014, the Vertex company talked about a "compassionate use program” [comment of the translator: a compassionate use program describes the tolerated usage of a drug that is not licensed for humanitarian reasons] for people who really need a new ...
- 06.10.2014
- Treated with Kalydeco®. And then?
- Hello, patients receiving a treatment like Kalydeco®, do they have a different life? I mean by that, do they still need to take many drugs such as Creon®, do they still do a lot of physiotherapy? Or it is case by case? Is there an increase in life expectancy, but is their life a little more ...
- 15.09.2014
- Vertex - results of a phase 2 study for patients heterozygous for F508del
- Hello The Vertex company has published results regarding patients heterozygous for the F508del mutation, here is the link: http://investors.vrtx.com/releasedetail.cfm?releaseid=862727. It seems to me that patients heterozygous for the F508del mutation could have a potential treatment like the one ...
- 15.09.2014
- F508del mutation treatment
- Hello, following the results released yesterday by Vertex to treat patients with two delta F508 mutations, what it about the patients with only one delta F508 mutation? In fact, when our son was born in 2011 we were told that there will be a cure for one of the two mutations, but for now I can ...
- 10.09.2014
- Ivacaftor-lumacaftor combination in F508del homozygous patients
- Could you give us some details for the double deltaF508 mutation? Is the Ivacaftor - lumacaftor combination study positive and in that case, how long will it take until market authorization for those drug and to treat a large proportion of sick patients. Thank you in advance for your response.
- 10.09.2014
- Ivacaftor and Lumacaftor
- The results of the phase 3 study have been published a few days ago. There were slight improvements in the 24-weeks study. How can I judge the resutls realistically for the future (timely manner, in case of long-term intake change of the mean life expectancy)? Many thanks for your time
- 21.08.2014
- Colloidal silver
- Can colloidal silver be taken for fighting bacteria in case of CF and can it also be inhaled? Is there any recent research?
- 21.08.2014
- Kalydeco® and body height
- Dear expert team, I have already wrote to you once concerning the off-label use of Kalydeco® with my son Till. He is taking now Kalydeco® for 10 weeks. He is 8-years old and has the mutation 1717 1G>A and the gating mutation S549R. Kalydeco® has a very good effect in him without negative side ...
- 18.08.2014
- Last results of the phase 3 cinical trial VX661 and ivacaftor
- Hello could you inform us regarding results of the clinical phase 3 which has just ended with patients homozygous for the F508del mutation and performed by the Vertex company. Thank you
- 29.07.2014